DRG Epidemiology’s coverage of actinic keratosis (AK) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of AK for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s AK forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AK over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following actinic keratosis subpopulations:
Prevalence of Actinic Keratosis per 100 Among People Aged 30+ in 2021 and 2031.tttttttt
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Actinic Keratosis over the Next Ten Yearsttttttttt
Analysis of the Prevalent Cases of Actinic Keratosis in 2021 by the Number of Lesionsttttt
Epidemiology Data
Methods
Total Prevalent Cases
Total Prevalent Cases by Number of Lesions
Reference Materials
Literature Review
Studies Included in the Analysis of Actinic Keratosis
Studies Excluded from the Analysis of Actinic Keratosis
Risk/Protective Factors
Risk/Protective Factors for Actinic Keratosis
Bibliography
Abbreviations
Glossary
Stephanie Niquita
Stephanie Niquita Phankon, M.B.B.S., M.P.H.,is a senior epidemiologist at DRG, part of Clarivate. She trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects. She holds an M.P.H. specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China.
